Clinical trials: Metastatic Kidney Cancer
Renal Cell Carcinoma, Circulating Tumor Cell
Circulating Tumor Cell Reducing No-touch Nephrectomy
This study will study circulating tumor cell (CTC) release during laparoscopic radical nephrectomy (LRN) for RCC. The main objective is to determine if CTC release can be reduced during RN by using a no-touch technique, with an…
- Trial name
- CITO-CERENE (NCT05070637)
- Testing
- No-touch laparoscopic radical nephrectomy, Conventional laparoscopic radical nephrectomy, Laparoscopic total nephrectomy control arm
- Where
- Portugal
- Volunteers
- 44 people
- Sponsor
- Hospital de Santa Maria, Portugal
Kidney Cancer
Carboxyamidotriazole in Treating Patients With Advanced Kidney Cancer
RATIONALE: Carboxyamidotriazole may stop the growth of kidney cancer by stopping blood flow to the tumor. PURPOSE: Phase II trial to study the effectiveness of carboxyamidotriazole in treating patients who have advanced kidney…
- Trial name
- NCT00005045
- Testing
- carboxyamidotriazole
- Where
- 55 sites in United States, Puerto Rico and 1 more
- Sponsor
- Eastern Cooperative Oncology Group
Metastatic Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8
Focused Radiation Versus Systemic Therapy for Kidney Cancer Patients With Limited Metastasis, SOAR Study
This phase III trial compares the effect of stero-ablative radiotherapy (SAbR) followed by standard of care systemic therapy, to standard of care systemic therapy alone, in patients with kidney cancer that has spread from where…
- Trial name
- NCT05863351
- Testing
- Computed Tomography, Magnetic Resonance Imaging, Questionnaire Administration
- Where
- 108 sites in United States
- Volunteers
- 472 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Metastatic Renal Cell Carcinoma
Study Using FolateScan to Identify Subjects With Folate Receptor-Positive Metastatic Renal Cell Carcinoma
Phase 2, multi-center, open-label, single-treatment group, baseline-controlled study to identify subjects with Folate Receptor-Positive Metastatic Renal Cell Carcinoma
- Trial name
- NCT01689766
- Testing
- Technetium Tc 99m EC20
- Where
- 2 sites in United States
- Volunteers
- 150 people
- Sponsor
- Endocyte
Kidney Cancer
ZD 1839 in Treating Patients With Metastatic Kidney Cancer
RATIONALE: Some tumors need growth factors produced by the body's white blood cells to keep growing. Drugs such as ZD 1839 may interfere with the growth factors and cause tumor cells to die.
- Trial name
- NCT00012337
- Testing
- gefitinib
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Aggressive Variant Prostate Carcinoma, Castration-Resistant Prostate Carcinoma
DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers
This phase Ib trial studies the side effects and best dose of DS3201 when given together with and ipilimumab for the treatment of patients with prostate, urothelial, or renal cell cancer that has spread to other places in the…
- Conditions
- Aggressive Variant Prostate Carcinoma, Castration-Resistant Prostate Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Metastatic Malignant Solid Neoplasm
- Trial name
- NCT04388852
- Testing
- Ipilimumab, Valemetostat
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- M.D. Anderson Cancer Center
Head and Neck Squamous Cell Carcinoma, Metastatic Renal Cell Cancer
Radiation Therapy and MK-3475 for Patients With Recurrent/Metastatic Head and Neck Cancer, Renal Cell Cancer, Melanoma, and Lung Cancer
This randomized clinical trial studies radiation therapy and MK-3475 in treating patients with head and neck cancer, kidney cancer, melanoma, or lung cancer that has returned, has spread to other parts of the body, or cannot be…
- Conditions
- Head and Neck Squamous Cell Carcinoma, Metastatic Renal Cell Cancer, Recurrent Head and Neck Carcinoma, Recurrent Lung Carcinoma
- Trial name
- NCT02318771
- Testing
- Radiation Therapy (RT), MK-3475
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Kidney Cancer, Metastatic Cancer
Sunitinib in Treating Patients With Kidney Cancer That Has Spread to the Brain
RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00814021
- Testing
- sunitinib malate
- Where
- France
- Volunteers
- 21 people
- Sponsor
- Institut Claudius Regaud
Advanced Solid Tumors
Study of Continuous OSI-906 Dosing
Multicenter, open-label, phase 1, cohort dose escalation study to determine the Maximum Tolerated Dose (MTD) on both Once Daily (QD) and Twice Daily (BID) schedules.
- Trial name
- NCT00514007
- Testing
- OSI-906
- Where
- 2 sites in United States, United Kingdom
- Volunteers
- 95 people
- Sponsor
- Astellas Pharma Inc
Metastatic Clear Cell Renal Cell Carcinoma
High Dose IL-2 and Stereotactic Ablative Body Radiation Therapy for Metastatic Renal Cancer
In this i-SABR (immunotherapy + Stereotactic Ablative Body Radiation) trial, the stereotactic radiation to multiple metastatic sites is delivered not only to eradicate sites of bulky progressive disease, but also to provide…
- Trial name
- NCT01896271
- Testing
- IL-2, Stereotactic Ablative Body Radiation Therapy
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Texas Southwestern Medical Center
Metastatic Renal Cell Carcinoma, Metastatic Melanoma
Aldesleukin in Participants With Metastatic Renal Cell Carcinoma or Metastatic Melanoma
This study evaluated the pharmacokinetics of aldesleukin in participants with metastatic renal cell cancer or metastatic melanoma.
- Trial name
- NCT00414765
- Testing
- Aldesleukin
- Where
- 4 sites in United States
- Volunteers
- 26 people
- Sponsor
- Novartis Pharmaceuticals
Metastatic Clear Cell Renal Cell Carcinoma
Validation of a Predictive Nomogram of Response or Resistance to Targeted Therapies in Metastatic Clear Cell Renal Cell Carcinoma
The purpose of this study is to validate of a predictive nomogram of response or resistance to targeted therapies in metastatic clear cell renal cell carcinoma
- Trial name
- RTKI (NCT02848768)
- Testing
- Sunitinib
- Where
- France
- Volunteers
- 45 people
- Sponsor
- Rennes University Hospital
ccRCC, Renal Cell Carcinoma (Kidney Cancer)
Phase 3 Study to Assess Safety and Efficacy of 177Lu-TLX250 in Advanced Relapsed or Recurrent ccRCC
Multicenter Phase 3 study of 177Lu-TLX250 in adult participants with CAIX-expressing advanced, relapsed or recurrent clear cell renal cell carcinoma (ccRCC).
- Conditions
- ccRCC, Renal Cell Carcinoma (Kidney Cancer), Renal Cell Carcinoma (RCC), Renal Cell Cancer Metastatic
- Trial name
- LUTEON (NCT07197580)
- Testing
- 177Lu-TLX250
- Where
- 5 sites in Australia
- Volunteers
- 40 people
- Sponsor
- Telix Pharmaceuticals (Innovations) Pty Limited
Renal Cell Cancer, Neoplasm Metastasis
Effect of Zoledronic Acid in Patients With Renal Cell Cancer and Bone Metastasis
It is the aim of this clinical study to evaluate the skeletal-related event rate under therapy with zoledronic acid in patients with renal cell cancer having at least one cancer-related bone lesion.
- Trial name
- NCT00172003
- Testing
- Zoledronic acid
- Where
- Germany
- Volunteers
- 50 people
- Sponsor
- Novartis Pharmaceuticals
Kidney Cancer
Tinzaparin in Treating Patients With Metastatic Kidney Cancer That Cannot Be Removed By Surgery
RATIONALE: Tinzaparin may stop the growth of kidney cancer by blocking blood flow to the tumor. PURPOSE: This phase I/II trial is studying the side effects of tinzaparin and to see how well it works in treating patients with…
- Trial name
- NCT00293501
- Testing
- tinzaparin sodium
- Where
- 3 sites in United States
- Volunteers
- 35 people
- Sponsor
- University of Vermont
Cancer
Valacyclovir in Preventing Cytomegalovirus Infection in Patients Who Are Undergoing Donor Stem Cell Transplantation
RATIONALE: Antivirals such as valacyclovir act against viruses and may be effective in preventing cytomegalovirus. It is not yet known if valacyclovir is effective in preventing cytomegalovirus in patients undergoing stem cell…
- Trial name
- NCT00045292
- Testing
- acyclovir, acyclovir sodium, valacyclovir
- Where
- 6 sites in United States
- Sponsor
- Fred Hutchinson Cancer Center
Carcinoma, Renal Cell, Clear-cell Metastatic Renal Cell Carcinoma
Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Renal Cell Carcinoma
TITAN RCC (0216-ASG) is a Phase 2, open-label study of nivolumab monotherapy with additional nivolumab/ipilimumab "boost" cycles in previously untreated and pretreated (2nd line), advanced or metastatic renal cell carcinoma…
- Trial name
- TITAN-RCC (NCT02917772)
- Testing
- Nivolumab/Ipilimumab
- Where
- 35 sites in Austria, Belgium and 6 more
- Volunteers
- 200 people
- Sponsor
- AIO-Studien-gGmbH
Cervical Cancer, Microsatellite Instability (MSI)-High Endometrial Cancer
A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies
The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of INCAGN02385 in participants with advanced malignancies.
- Conditions
- Cervical Cancer, Microsatellite Instability (MSI)-High Endometrial Cancer, Gastric Cancer (Including Stomach and Gastroesophageal Junction [GEJ]), Esophageal Cancer
- Trial name
- NCT03538028
- Testing
- INCAGN02385
- Where
- 4 sites in United States
- Volunteers
- 22 people
- Sponsor
- Incyte Biosciences International Sàrl
Metastatic Renal Cancer, Stage III Renal Cell Cancer
Safety and Compliance of Renal Cancer Patients Treated by Non-IV Drugs
Generally, in the trials, an observant patient is described as correctly taking 90 to 100% of the prescribed doses. Here, the 80% compliance rate will be the cut-off between observant and non-observant patients.
- Trial name
- TOPTACOS (NCT03630692)
- Testing
- observance of oral drug treatment
- Where
- 14 sites in France
- Volunteers
- 158 people
- Sponsor
- Institut Cancerologie de l'Ouest
Metastatic Renal Cell Carcinoma, Metastatic Melanoma
PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy
The purpose of this registry is to collect information on patients who are receiving treatment with Proleukin in an organized way, and to learn more about patient care during and after treatment.
- Trial name
- NCT01415167
- Where
- 45 sites in United States
- Volunteers
- 1,690 people
- Sponsor
- Prometheus Laboratories